Literature DB >> 17920046

Postischemic administration of HMG CoA reductase inhibitor inhibits infarct expansion after transient middle cerebral artery occlusion.

Shiro Sugiura1, Yoshiki Yagita, Tsutomu Sasaki, Kenichi Todo, Yasukazu Terasaki, Naoki Ohyama, Masatsugu Hori, Kazuo Kitagawa.   

Abstract

Infarcts expand over a period of several days after focal cerebral ischemia. Inhibition of infarct expansion would be a promising strategy for the protection of the brain after ischemic insult. In this study, we examined the effect of statin treatment initiated 2 days after transient occlusion of the middle cerebral artery for 80 min. Treatment with continuous infusion of pravastatin with an osmotic minipump for 6 days resulted in a significantly smaller infarct volume and better recovery of motor function at 8 days after ischemia compared to vehicle treatment. These results suggest that statin treatment during the postischemic period may be effective in stroke patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17920046     DOI: 10.1016/j.brainres.2007.08.069

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  4 in total

1.  Comparison of the post-embolization effects of tissue-plasminogen activator and simvastatin on neurological outcome in a clinically relevant rat model of acute ischemic stroke.

Authors:  Kama Z Guluma; Paul A Lapchak
Journal:  Brain Res       Date:  2010-07-29       Impact factor: 3.252

2.  Statin post-treatment provides protection against simulated ischemia in bovine pulmonary arterial endothelial cells.

Authors:  Xing Wu; Daowei Lin; Guofu Li; Zhiyi Zuo
Journal:  Eur J Pharmacol       Date:  2010-03-31       Impact factor: 4.432

Review 3.  CD36: a multi-modal target for acute stroke therapy.

Authors:  Sunghee Cho; Eunhee Kim
Journal:  J Neurochem       Date:  2009-05       Impact factor: 5.372

Review 4.  Nitric oxide: considerations for the treatment of ischemic stroke.

Authors:  Nicole A Terpolilli; Michael A Moskowitz; Nikolaus Plesnila
Journal:  J Cereb Blood Flow Metab       Date:  2012-02-15       Impact factor: 6.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.